Wegovy Pill Approved in Europe and US: What to Know About the Weight Loss Drug Revolution

# Wegovy in 2025: The Weight Loss Drug Reshaping Medicine, Markets, and Global Policy

**A deep-dive podcast episode on how Novo Nordisk's blockbuster obesity drug became a geopolitical and medical phenomenon**

In this comprehensive episode, host Alexandra Reeves unpacks the rapid evolution of Wegovy from a niche weight-loss injection into one of the most consequential pharmaceutical stories of the decade. Covering everything from European Union approval of the oral semaglutide pill to Medicare's controversial new "GLP-1 Bridge" program, this episode connects the dots between drug science, regulatory battles, and real-world patient access.

**Key topics covered in this episode:**

- **European approval milestone**: How the European Commission's authorization of the Wegovy pill—with trial results showing 17% average body weight loss—opens the door to all 27 EU countries, following the UK's early lead as the first European nation to approve an oral GLP-1 treatment - **The US prescription wars**: Fresh IQVIA data revealing Wegovy's pill capturing an 89% market share over Eli Lilly's competing Foundayo, and what this dominance means for the broader weight-loss drug industry - **Higher-dose Wegovy HD**: New injectable dosing achieving 21% body weight loss, closing the gap with rival Mounjaro - **Beyond weight loss**: Wegovy's newly approved use in India for treating MASH (a serious liver disease), plus emerging research suggesting semaglutide may slow biological aging markers in HIV patients - **Safety concerns**: A sobering look at FDA adverse event data linking Wegovy to a rare eye condition called ischemic optic neuropathy, alongside a formal FDA warning letter to Novo Nordisk over incomplete side-effect reporting - **Supply chain shifts**: The end of the semaglutide shortage crisis and the FDA's proposed crackdown on compounded versions of the drug - **Access and affordability**: A critical breakdown of Medicare's new $50/month GLP-1 Bridge program—including hidden limitations and the looming 2027 policy cliff that could leave vulnerable patients stranded - **Older adults and obesity treatment**: New STEP trial data showing adults over 65 achieving comparable results to younger patients, challen

Some great Deals https://amzn.to/49SJ3Qs

For more check out http://www.quietplease.ai